high mobility group nucleosome binding domain 1 pseudogene 7Genealiases: []
Q-omics provides the consensus-scored HMGN1P7 profile across patient tissues and cancer cell-line models. HMGN1P7 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, HMGN1P7 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, HMGN1P7 RNA expression shows 12,574 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CHOL, HNSC, and THYM as cancer lineages where HMGN1P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN1P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN1P7 survival associations across molecular data types. HMGN1P7 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN1P7 RNA expression–survival associations across cancer types. High HMGN1P7 expression shows unfavorable associations in CHOL, BLCA, PAAD and LUAD, but favorable associations in HNSC and LIHC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify CHOL as the clearest survival context for HMGN1P7 RNA expression.
This table summarizes HMGN1P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN1P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN1P7 shows lower tumor expression in HNSC, KIRC, BRCA, COAD, LUAD and LUSC. The HNSC box plot shows higher HMGN1P7 RNA expression in normal versus tumor tissue (log2 FC = −0.510, t-test p < 0.001).
This table shows molecular features associated with HMGN1P7 in patient tissues and cancer cell lines. In patient samples, HMGN1P7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
